Novanta Inc. · NASDAQ:NOVT

Novanta — Baird's 2023 Global Industrial Conference

21 slides from Novanta's conference presentation, Nov 8, 2023

  1. Slide 1: A Trusted Technology Partner

    @ Novanta A Trusted Technology Partner NOVEMBER 2023

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in thi

  3. Slide 3: A Trusted, Sole-Sourced Technology Partner to Leading Global OEMs

    A Trusted, Sole-Sourced Technology Partner to >$878M Leading Global OEMs Revenue ~60% outside of the US We enable productivity improvement in healthcare and industrial markets with secular growth >$193M APPLICATION AREAS ADVANCED INDUSTRIAL MEDICAL Adjusted EBITDA +22% of sales Robotics & Automation

  4. Slide 4: Our Strategy

    Our Strategy WHERE WE PLAY HOW WE PLAY AND WIN HOW WE ACCELERATE Win in High Innovation Novanta Culture– Disciplined Growth Segments Growth System Novanta Way Acquisitions CONFIDENTIAL AND PROPRIETARY

  5. Slide 5: Where We Play & How We Win

    Where We Play & How We Win Technology leadership Asset light in HGMs Growth Returns business model RE V E N UE C A S H F L OW Sticky business model with Allocate based on cash- winning OEMs on-cash return TAM expansion through NPI Expand gross margins and Subsystems and improve cash flow Accretive M

  6. Slide 6: The Novanta Transformation Journey

    The Novanta Transformation Journey ~$1B 19 Capital deployed for transactions M&A ~$860M ~3.5X Revenue Growth ~50% Vitality Index Single ~25% of sales digits ~$240M ~50% ~90% ~10% Subsystem Sales 2012 Sales 2022 Sales Single ~30% of sales Medical Advanced Industrial digits CONFIDENTIAL AND PROPRIETAR

  7. Slide 7: Precision Medicine and Manufacturing

    Precision Medicine and Manufacturing SEGMENT OVERVIEW KEY METRICS KEY APPLICATIONS KEY TECHNOLOGIES SUBSYSTEMS ~$275M REVENUE Medical 48% Advanced LASER-BASED DNA SEQUENCE ADJUSTED GM% Industrial MATERIAL DECODING Optical Light Scan Heads PROCESSING Engine 8% COMPONENTS REVENUE CAGR SINCE 2016 MACRO

  8. Slide 8: Subsystem Example: Intelligent Laser Beam Steering

    Subsystem Example: HIGH-SINGLE-DIGIT Intelligent Laser Beam Steering LONG-TERM MARKET GROWTH RATE Never before possible throughput, precision and miniaturization Increasing $ content and stickiness with customers, through intelligent subsystem products EXAMPLE APPLICATIONS: LASER ADDITIVE MANUFACTUR

  9. Slide 9: Robotics and Automation

    Robotics and Automation SEGMENT OVERVIEW KEY METRICS KEY APPLICATIONS KEY TECHNOLOGIES SUBSYSTEMS ~$308M REVENUE Medical 49% Advanced ROBOTICS AND ROBOTIC Robotic Joints Mechatronics ADJUSTED GM% Industrial AUTOMATION SURGERY 23% COMPONENTS REVENUE CAGR SINCE 2016 MACROECONOMIC DRIVERS Controls & Pr

  10. Slide 10: Converging Technology Solutions for Robotic Applications

    Converging Technology Solutions DOUBLE-DIGIT for Robotic Applications LONG-TERM MARKET GROWTH RATE <25% PENETRATION OF ROBOTICS APPLICATIONS Strong presence, brand MOTION CONTROL recognition and value Precise motion via motors, drives, and mechatronics proposition Highly engineered, end- SENSING eff

  11. Slide 11: Leading Technology Provider to Robotic Surgery Applications

    Leading Technology Provider DOUBLE-DIGIT to Robotic Surgery Applications LONG-TERM MARKET GROWTH RATE Precision and proprietary technologies optimized for the most demanding applications <5% penetration of surgical robotics applications PRECISION MOTION AND FLUID / GAS MANAGEMENT SOLUTIONS FOR ROBOT

  12. Slide 12: Medical Solutions

    Medical Solutions SEGMENT OVERVIEW KEY METRICS KEY APPLICATIONS KEY TECHNOLOGIES Advanced SUBSYSTEMS ~$278M Industrial REVENUE 41% Medical MINIMALLY INVASIVE ROBOTIC ADJUSTED GM% SURGERY SURGERY Endoscopic Insufflators iOR Surgical Displays Pumps Devices 15% REVENUE CAGR SINCE 2016 COMPONENTS MACROE

  13. Slide 13: Medical Growth Application: Surgical Smoke Removal

    Medical Growth Application: DOUBLE-DIGIT Surgical Smoke Removal LONG-TERM MARKET GROWTH RATE APPLICATION CAPABILITY High growth medical market opportunity, estimated at 20% per year Integrated smoke evacuation increases safety, optimizes workflow and eliminates separate equipment INTEGRATED INSUFFLA

  14. Slide 14: Intelligent Solutions for Advanced Diagnostics

    Intelligent Solutions for HIGH-SINGLE-DIGIT Advanced Diagnostics LONG-TERM MARKET GROWTH RATE <5% OF WORLD’S DNA SEQUENCED BARCODE RFID READER (sample scanning) (reagent & sample tracking) Enabling automation and cutting-edge capabilities for advanced diagnostics equipment Supporting clinical adopti

  15. Slide 15: How We Operate: Novanta Way Culture

    HOW WE OPERATE COHESIVE ENGAGED TEAMS EMPLOYEES Diverse, inclusive, Engage around a shared collaborative: committed vision and purpose to win Best Practices Owner Mindset Talent and Capital Novanta NOVANTA Business units with Leverage agility, speed, customer Allocation WAY CULTURE focus. Scale Nova

  16. Slide 16: Delivering Consistent Financial Results

    Delivering Consistent Financial Results REVENUE ADJUSTED EBITDA FINANCIAL $878M to FRAMEWORK $884M $193M to $861M $196M Mid to high single-digit organic $183M growth +12% Double-digit reported CAGR growth through acquisitions +15% CAGR 100 bps per year of gross margin expansion $244M Strong free cas

  17. Slide 17: Delivering Where It Matters Most

    Delivering Where It Matters Most Minimally Invasive Surgery Robotics and Automation Life Sciences In Vitro Diagnostics Robotic Surgery Patient Monitoring Laser Additive Manufacturing Ophthalmology Laser-based Material Processing CONFIDENTIAL AND PROPRIETARY

  18. Slide 18: Novanta Operating Groups and Businesses

    Novanta Operating Groups and Businesses PRECISION MEDICINE MEDICAL ROBOTICS AND AUTOMATION AND MANUFACTURING SOLUTIONS ~32% OF TOTAL ~32% OF TOTAL ~36% OF TOTAL COMPANY SALES COMPANY SALES COMPANY SALES DE TE CTION & AN ALYSIS MIN IMALLY IN VASIVE SURGE RY CONFIDENTIAL AND PROPRIETARY

  19. Slide 19: Environment, Sustainability and Governance

    Environment, Sustainability and Governance REPORTING ACCORDING TO SASB AND TCFD STANDARDS NOVANTA ESG TARGETS Long-term goal to achieve net zero 1 greenhouse gas (GHG) emissions by 2050 Provide employees with one day of paid time-off (PTO) 2 to volunteer at an approved non-profit organization 3 Expa

  20. Slide 20: Use of Non-GAAP Measures

    Use of Non-GAAP Measures The non-GAAP financial measures used in this presentation are Adjusted EBITDA and Adjusted Gross Profit Margin. The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Co

  21. Slide 21: Non-GAAP Reconciliation

    Non-GAAP Reconciliation NINE (in thousands of dollars) TWELVE MONTHS ENDED MONTHS ENDED Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec31, Dec 31, Sep 29, 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 REVENUE Revenue (GAAP) $243,796 $316,910 $364,706 $373,59

Novanta — Baird's 2023 Global Industrial Conference on 6ix